Genomics has been treading water for the past six months, holding steady at $14.80. The stock also fell short of the S&P ...

10x Genomics (TXG) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...

Torex Gold Resources (TXG.TO) said Thursday that it expects to hit the low end of its 2025 silver eq Premium MT Newswires • 23 days ago TXG.TO +0.44% SI=F ...

Investors in 10x Genomics Inc (Symbol: TXG) saw new options become available today, for the January 2024 expiration. One of the key data points that goes into the price an option buyer is willing ...

10x Genomics, Inc. (TXG) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions, dividends, ratings.

Investors in 10x Genomics Inc (Symbol: TXG) saw new options become available this week, for the May 2025 expiration. One of the key inputs that goes into the price an option buyer is willing to ...

Summary I assign TXG a buy rating with a 1-year price target of $12.7 per share, projecting an 18% upside YoY. TXG's new lower-cost Chromium offerings could drive volume growth and increased ...

A small number of hedge funds were also right about betting on TXG as the stock returned 22.6% since the end of the third quarter (through 12/18) and outperformed the market by an even larger margin.

10x Genomics (TXG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.